8-K: RenovoRx Faces Nasdaq Delisting Threat Over Bid Price

RenovoRx, Inc. received a deficiency notice from Nasdaq for failing to maintain the $1.00 minimum bid price, initiating a 180-day compliance period.

Summary

• RenovoRx, Inc. (the "Company") received a deficiency notice from The Nasdaq Stock Market on December 31, 2025.
• The notice informed the Company that its common stock failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
• This non-compliance was due to the closing bid price of the Common Stock being below $1.00 for 32 consecutive business days prior to the notice date.
• The notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital Market.
• The Company has an initial compliance period of 180 calendar days, until June 30, 2026, to regain compliance.
• To regain compliance, the closing bid price must meet or exceed $1.00 per share for a minimum of ten consecutive business days.
• If compliance is not met by June 30, 2026, the Company may be eligible for an additional 180-day compliance period if it meets other listing requirements and provides written notice of intent to cure, potentially through a reverse stock split.
• Failure to regain compliance after all periods could lead to Nasdaq notifying the Company of its determination to delist the Common Stock, with an opportunity to appeal.

Sentiment

Score: 3

Explanation: The filing indicates a significant negative event (Nasdaq deficiency notice) with potential severe consequences (delisting). While there's a compliance period, the underlying issue of low stock price is concerning. The risk of delisting and potential reverse stock split weighs heavily on sentiment.

Negatives

• The Company's common stock failed to meet the Nasdaq minimum bid price requirement of $1.00 per share.
• The stock traded below $1.00 for 32 consecutive business days, triggering a deficiency notice.

Risks

• Potential delisting of the Common Stock from The Nasdaq Capital Market if compliance is not regained.
• The need to potentially effect a reverse stock split to cure the deficiency, which can be dilutive or negatively perceived by investors.
• Failure to qualify for an additional compliance period if other listing standards are not met.
• Negative impact on investor confidence and stock liquidity due to the delisting threat.

Future Outlook

The Company's immediate future outlook is focused on regaining compliance with Nasdaq's minimum bid price requirement. This involves ensuring the common stock trades at or above $1.00 for at least ten consecutive business days by June 30, 2026. If unsuccessful, the Company may pursue an additional compliance period, potentially involving a reverse stock split, to avoid delisting.

Management Comments

• Shaun R. Bagai, Chief Executive Officer, duly signed the report on behalf of RenovoRx, Inc., acknowledging the receipt of the Nasdaq deficiency notice and the Company's current listing status.

Industry Context

Maintaining minimum bid price requirements is a standard listing rule across major stock exchanges like Nasdaq, designed to ensure a certain level of market stability and investor confidence. Companies that fall below these thresholds often face similar compliance challenges, which can impact their ability to attract institutional investors and maintain liquidity compared to peers.

Comparison to Industry Standards

• Nasdaq Listing Rule 5550(a)(2) requires a minimum bid price of $1.00, a common standard among major U.S. exchanges to ensure a certain quality and stability of listed securities.
• Many small-cap biotechnology and medical device companies, similar to RenovoRx, often face challenges in maintaining this bid price, especially during periods of clinical trial setbacks or market downturns, leading to similar deficiency notices.
• Companies like Aytu BioPharma (AYTU) or Sio Gene Therapies (SIOX) have previously faced similar Nasdaq compliance issues, often resorting to reverse stock splits to regain compliance, which can be a common, albeit often negatively perceived, strategy in the industry.

Stakeholder Impact

• Shareholders: Potential negative impact on share value, liquidity, and investor confidence due to delisting risk and potential reverse stock split.
• Employees: Potential uncertainty regarding the company's future listing status and market perception.

Next Steps

• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by June 30, 2026.
• Ensure the closing bid price of the Common Stock is $1.00 or higher for at least ten consecutive business days.
• If necessary, consider strategies such as a reverse stock split to cure the deficiency.
• If unable to regain compliance, prepare to meet criteria for a second 180-day compliance period.
• Prepare for a potential appeal to a Hearings Panel if Nasdaq determines to delist the Common Stock.

Key Dates

Recommendation

The company faces a significant challenge with the Nasdaq delisting notice due to its low bid price. While there is a compliance period and potential remedies like a reverse stock split, the uncertainty and the underlying weakness in stock performance warrant caution. Investors should hold existing positions to monitor the company's efforts to regain compliance, but new investment is not recommended until the listing status is secured and the operational performance improves.

Keywords

RenovoRx, RNXT, Nasdaq, delisting, minimum bid price, compliance, 8-K filing, stock market, reverse stock split